B

Braveheart Bio

Develops cardiac myosin inhibitors for HCM

Accounting Manager

Financial AccountingConfirmed live in the last 24 hours
Full-timeSan Francisco, CA, USAIn-person

About the Job

Requirements

  • At least 5 years of progressive finance and accounting experience.
  • A bachelor's degree in accounting or a related field.
  • Deep technical accounting knowledge of U.S. GAAP, including research and development accruals and clinical trial accounting.
  • Advanced proficiency in Microsoft Excel, including XLOOKUP and INDEX/MATCH.
  • Strong knowledge of public company requirements, internal controls under the Sarbanes-Oxley Act, and cross-functional alignment.
  • Experience supporting audits conducted by a Big Four or national accounting firm.
  • Strong written and verbal communication skills.

Responsibilities

  • Support the monthly accounting close process, ensuring a timely and accurate close within external and internal reporting deadlines, and support financial planning and analysis budget-to-actual reporting.
  • Review journal entries and reconciliations prepared by accounting team members; supervise, mentor, and develop junior accounting staff.
  • Prepare clinical trial accruals, including reviewing clinical contracts, contract research organization reports, patient costs, site costs, and invoices; liaise with internal stakeholders and clinical vendors to ensure accruals are complete, accurate, and timely.
  • Implement policies and procedures for accounting activities and functions, maintain internal controls in areas of responsibility, and improve and streamline processes where appropriate.
  • Support annual audits, quarterly financial reviews, internal controls testing, system implementations, and other projects as needed.

Desired Qualifications

  • Experience with publicly traded, pre-IPO, or clinical-stage biotechnology or life sciences companies.
  • A certified public accountant license.
  • Public accounting experience.
  • Experience with NetSuite.

About the Company

Braveheart Bio

Develops cardiac myosin inhibitors for HCM

Braveheart Bio develops therapies for hypertrophic cardiomyopathy by in-licensing promising drug candidates and advancing them through late-stage clinical trials. Its lead drug, BHB-1893, is a selective small-molecule cardiac myosin inhibitor licensed from Hengrui Pharma for ex-China rights, designed to reduce contractility in heart cells and improve heart performance. The company differentiates itself by pursuing a best-in-class profile with potential improvements in efficacy, safety, and dosing, supported by a high-profile leadership team and investors. Its goal is to bring an approved, globally accessible therapy for HCM that delivers meaningful clinical benefit.

Company size
51-200
Company stage
IPO
Headquarters
San Francisco, CA
Founded
2025

Recently Posted Jobs

Explore more opportunities at Braveheart Bio

See more jobs